Abstract:Background In 2020, the current outbreak of Coronavirus Disease 2019(COVID-19) has constituted a global pandemic. But the question about the immune mechanism of patients with COVID-19 is unclear and cause particular concern to the world. Here, we launched a follow-up analysis of antibodies against SARS-CoV-2 of 192 COVID-19 patients, aiming to depict a kinetics profile of antibodies against SARS-CoV-2 and explore the related factors of antibodies expression against SARS-CoV-2 in COVID-19 patient. Methods A total of 192 COVID-19 patients enrolled in the designated hospital of Guangzhou, Guangzhou Eighth People’s Hospital, from January to February 2020 were selected as the study cohort. A cohort of 130 COVID-19 suspects who had been excluded from SARS-CoV-2 infected by negative RT-PCR result and 209 healthy people were enrolled in this study. Detection of IgM and IgG against SARS-CoV-2 were performed by Chemiluminescence immunoassay in different groups. Results It has been found that the seroconversion time of IgM against SARS-CoV-2 in most patients was 5-10 days after the symptoms onset, and then rose rapidly, reaching a peak around 2 to 3 weeks, and the median peak concentration was 2.705 AU / mL. The peak of IgM maintained within one week, and then enters the descending channel. IgG seroconverted later than or synchronously with IgM, reaching peaks around 3 to 4 weeks.The median peak concentration was 33.998AU / ml,which was higher than that of IgM. IgM titers begins to gradually decrease after reaching the peak in the 4th week, after the 8th week, a majority of IgM in patient’s serum started to turn negative. On the contrary, titers of IgG began to decline slightly after the fifth week, and more than 90% of results of patients were positive after 8 weeks. Additionally, the concentration of antibodies positively correlated with the severity of the disease and the duration of virus exist in host. Conclusion We depict a kinetics profile of antibodies against SARS-CoV-2 in COVID-19 patients and found out that the levels of antibodies were related to the disease severity, age, gender and virus clearance or continuous proliferation of COVID-19 patients. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Guangzhou Science and Technology Program(No.202008010008),China ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All patients in this study have signed the informed consent, and the experimental protocol was approved by the Ethics Committee of Guangzhou Eighth People's Hospital,China(No.20200547) . All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The data that support the findings of this study are available from the corresponding author upon reasonable request.

A comparison study of SARS‐CoV‐2 IgG antibody between male and female COVID‐19 patients: A possible reason underlying different outcome between sex

Sex-based clinical and immunological differences in COVID-19

Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS CoV 2

Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients

Sex differences in immune responses that underlie COVID-19 disease outcomes

Evaluation of Sex‐related Hormones and Semen Characteristics in Reproductive‐aged Male COVID‐19 Patients

Sex Differences in Clinical Findings among Patients with Coronavirus Disease 2019 (COVID-19) and Severe Condition

Sex-Disaggregated Data on Clinical Characteristics and Outcomes of Hospitalized Patients With COVID-19: A Retrospective Study

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Sex Differences in Severity and Mortality Among Patients With COVID-19: Evidence from Pooled Literature Analysis and Insights from Integrated Bioinformatic Analysis

Age-Dependent Gender Differences In Covid-19 In Mainland China: Comparative Study

Sex Differences on Clinical Characteristics, Severity, and Mortality in Adult Patients With COVID-19: A Multicentre Retrospective Study

Study on the expression levels of antibodies against SARS CoV 2 at different period of disease and its related factors in 192 cases of COVID 19 patients

Distinct Clinical Characteristics and Risk Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-stratified, Large-scale Cohort Study in Wuhan, China

Association of sex with clinical outcomes in COVID-19 patients: A retrospective analysis of 1190 cases

Sars-Cov-2 Antibodies And Associated Factors At Different Hospitalization Time Points In 192 Covid-19 Cases

Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study

Sex differences in the outcome of critically Ill patients with COVID-19 - An international multicenter critical care consortium study

Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes

Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions

Sex- and age-specific clinical and immunological features of coronavirus disease 2019